Zydus gets US regulator’s PAS for generic version of Mycophenolate Mofetil for injection
PTI, Mar 21, 2022, 10:46 AM IST
New Delhi: Zydus Lifesciences Ltd on Monday said it has received prior approval supplement nod from the US health regulator to market its generic version of Mycophenolate Mofetil for injection used in combination with other drugs for prophylaxis of organ rejection in patients receiving renal, hepatic or cardiac transplants.
The Prior Approval Supplement (PAS) granted by the US Food & Drug Administration (USFDA) is for Mycophenolate Mofetil for injection of strength 500 mg/vial, the generic equivalent of CellCept injection, the company said in a regulatory filing.
As per the USFDA, PAS refers to a change in either manufacturing or testing of a product applicable to either a specific batch of product or all products that requires the regulator’s approval prior to implementation of such changes or sale of the product.
The company said the PAS it has received is for site transfer into Jarod. ”The injection will be manufactured at the group’s injectables manufacturing facility at Jarod near Vadodara in Gujarat. This site was recently inspected by the USFDA,” it added.
In September 2017, the group was granted approval to market Mycophenolate Mofetil for injection in the strength of 500 mg/vial. Mycophenolate Mofetil is indicated for use in combination with other drugs such as cyclosporine and corticosteroids for the prophylaxis of organ rejection in patients receiving renal, hepatic or cardiac transplants, the company said. The group now has 330 approvals and has so far filed over 400 abbreviated new drug applications since the commencement of the filing process in FY 2003-04, it added.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
The Role of Screening and Early Detection in Liver Cancer
Need to recognise obesity as chronic disease: Experts
Study reveals how gut microbes work with body clock in managing stress
Weight loss could help one manage PCOS symptoms, study suggests
Risk of abnormal blood fat levels increased by about 30 pc during pandemic, finds study
MUST WATCH
Latest Additions
Felling of trees: What is being done to restore Delhi Ridge? SC asks DDA
Kinnigoli: Truck carrying red stone collides with Auto-Rickshaw; driver injured
UP govt to install 150,000 toilets for Maha Kumbh, set up paying guest facilities
Kavoor Police arrest two notorious cattle thieves
Udupi: Unidentified body found near Bailkere’s Vidhyodaya School
Thanks for visiting Udayavani
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.